Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of Oral PX-478 (a HIF-1α Inhibitor) in Patients With Advanced Solid Tumors or Lymphoma

NCT00522652 is registered in ClinicalTrials.gov with Cascadian Therapeutics Inc. as lead sponsor.

NCT NCT00522652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of Oral PX-478 (a HIF-1α Inhibitor) in Patients With Advanced Solid Tumors or Lymphoma
Lead sponsor
Cascadian Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2007
Completion date
May 31, 2010
Enrollment
45 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, lymphoma